| 引用本文: | 江西省研究型医院学会,江西省药学会药物流行病学专业委员会.集中带量采购政策下江西省口服二氢吡啶类钙离子通道阻滞剂药品临床综合评价专家共识[J].中国现代应用药学,2023,40(23):3334-3340. |
| Jiangxi Research Hospital Association,Pharmacoepidemiology Committee of Jiangxi Pharmaceutical Society.Expert Consensus on the Comprehensive Clinical Evaluation of Oral Dihydropyridine Calcium Channel Blockers Under the Centralized Drug Volume-based Procurement Policy in Jiangxi Province[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(23):3334-3340. |
|
|
| 摘要: |
| 目的 开展口服二氢吡啶类钙离子通道阻滞剂的临床综合评价，为医疗机构降压药物的合理使用提供参考依据。方法 由南昌大学第二附属医院牵头，以江西省研究型医院学会及江西省药学会为依托，江西省25家三级甲等医院共同参与，运用文献综述及德尔菲法，通过项目启动、初稿形成后的2轮专题修订会研讨及1轮电子版反馈，最终制定本共识。结果 截至2022年2月，已纳入国家集中带量采购的钙离子通道阻滞剂2个。该共识采用百分制，从有效性、安全性、经济学、适宜性、可及性和创新性共6个维度，对涉及的10个钙离子通道阻滞剂进行了临床综合评价，并根据分值形成不同的推荐级别。结论 制定了《集中带量采购政策下江西省口服二氢吡啶类钙离子通道阻滞剂药品临床综合评价共识》，为国家和省级集中带量采购的约定采购量调整提供参考，同时也为医疗结构药品配备和采购目录的制定，药品科学化和精细化管理提供理论依据。 |
| 关键词: 集中带量采购 江西省 降压药 钙离子阻滞剂 临床综合评价 专家共识 |
| DOI：10.13748/j.cnki.issn1007-7693.20223990 |
| 分类号:R954 |
| 基金项目:国家自然科学基金项目(82000062，81960015) |
|
| Expert Consensus on the Comprehensive Clinical Evaluation of Oral Dihydropyridine Calcium Channel Blockers Under the Centralized Drug Volume-based Procurement Policy in Jiangxi Province |
|
Jiangxi Research Hospital Association, Pharmacoepidemiology Committee of Jiangxi Pharmaceutical Society
|
| Abstract: |
| OBJECTIVE To conduct the comprehensive clinical evaluation of oral dihydropyridine calcium channel blockers and to provide reference for rational use of antihypertensive drugs in medical institutions. METHODS Led by the Second Affiliated Hospital of Nanchang University, supported by Jiangxi Research Hospital Association and Pharmacoepidemiology Committee of Jiangxi Pharmaceutical Society, and 25 third grade class A hospitals in Jiangxi Province jointly participated, using literature review and Delphi method, through kick-off meeting, two rounds of revision discussion and one round of electronic feedback after draft was completed. Expert Consensus was finally formulated. RESULTS As of February 2022, there were 2 oral dihydropyridine calcium channel blockers that had been included in the centralized drug volume-based procurement of the state. The expert consensus adopted the percentage system for quantitative evaluation. The comprehensive clinical evaluation on 10 oral dihydropyridine calcium channel blockers involved in centralized drug volume-based procurement in Jiangxi Province was implemented from six dimensions including effectiveness, safety, economy, suitability, accessibility and innovation, and different recommendation levels were formed according to the scores. CONCLUSION The Expert consensus on the comprehensive clinical evaluation of oral dihydropyridine calcium channel blockers under the centralized drug volume-based procurement policy in Jiangxi Province is established, which provides reference for the adjustment of the agreed procurement volume of centralized procurement at the national and provincial levels, and also provides theoretical basis for the formulation of the medical structure drug allocation and procurement catalogue, scientific and refined drug management. |
| Key words: centralized drug volume-based procurement Jiangxi province antihypertensive drugs calcium channel blockers comprehensive clinical evaluation expert consensus |
